Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases 12,750 Shares of Biogen Inc. $BIIB

Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its position in Biogen Inc. (NASDAQ:BIIB) by 48.0% during the first quarter, Holdings Channel reports. The institutional investor owned 39,303 shares of the biotechnology company’s stock after purchasing an additional 12,750 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Biogen were worth $7,205,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Elevation Point Wealth Partners LLC acquired a new position in Biogen during the 1st quarter worth approximately $683,000. Platform Technology Partners acquired a new stake in shares of Biogen in the first quarter valued at approximately $220,000. Keybank National Association OH raised its holdings in shares of Biogen by 4.9% in the first quarter. Keybank National Association OH now owns 8,834 shares of the biotechnology company’s stock valued at $1,620,000 after purchasing an additional 416 shares during the last quarter. Root Financial Partners LLC lifted its position in shares of Biogen by 84.3% in the first quarter. Root Financial Partners LLC now owns 341 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 156 shares in the last quarter. Finally, USS Investment Management Ltd lifted its position in shares of Biogen by 8.8% in the first quarter. USS Investment Management Ltd now owns 37,217 shares of the biotechnology company’s stock worth $6,822,000 after purchasing an additional 3,001 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

Shares of BIIB opened at $216.12 on Monday. The company has a market cap of $31.91 billion, a PE ratio of 23.19 and a beta of 0.16. The firm has a 50-day moving average of $196.61 and a 200-day moving average of $187.11. Biogen Inc. has a one year low of $121.05 and a one year high of $219.72. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the prior year, the company earned $3.02 earnings per share. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities analysts forecast that Biogen Inc. will post 13.95 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on BIIB. The Goldman Sachs Group raised their target price on shares of Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Argus raised shares of Biogen to a “hold” rating in a research report on Thursday, April 9th. JPMorgan Chase & Co. raised their price objective on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a report on Thursday, April 23rd. Weiss Ratings raised Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 1st. Finally, Citigroup upped their target price on Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Biogen currently has an average rating of “Moderate Buy” and an average target price of $217.41.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.